共 50 条
EAN guideline on palliative care of people with severe, progressive multiple sclerosis
被引:0
|作者:
Solari, A.
[1
]
Giordano, A.
[1
,2
]
Sastre-Garriga, J.
[3
]
Kopke, S.
[4
,5
]
Rahn, A. C.
[5
]
Kleiter, I
[6
]
Aleksovska, K.
[7
]
Battaglia, M. A.
[8
]
Bay, J.
[9
]
Copetti, M.
[10
]
Drulovic, J.
[11
]
Kooij, L.
[12
]
Mens, J.
[12
]
Meza Murillo, E. R.
[3
]
Milanov, I
[13
]
Milo, R.
[14
,15
]
Pekmezovic, T.
[16
]
Vosburgh, J.
[17
]
Silber, E.
[18
]
Veronese, S.
[19
]
Patti, F.
[20
]
Voltz, R.
[21
,22
,23
]
Oliver, D.
[24
]
机构:
[1] Fdn IRCCS Ist Neurol Carlo Besta, Unit Neuroepidemiol, Via Celoria 11, I-20133 Milan, Italy
[2] Univ Turin, Dept Psychol, Turin, Italy
[3] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Multiple Sclerosis Ctr Catalonia Cemcat, Dept Neurol Neuroimmunol, Barcelona, Spain
[4] Univ Cologne, Inst Clin Nursing Sci, Cologne, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Inst Neuroimmunol & Multiple Sclerosis, Hamburg, Germany
[6] Behandlungszentrum Kempfenhausen Multiple Skleros, Marianne Strauss Klin, Berg, Germany
[7] European Acad Neurol, Vienna, Austria
[8] Univ Siena, Dept Life Sci, Siena, Italy
[9] People MS Advisory Comm, Multiple Sclerosis Int Federat, Copenhagen, Denmark
[10] Fdn IRCCS Casa Sollievo Sofferenza, Unit Biostat, San Giovanni Rotondo, Italy
[11] Univ Belgrade, Fac Med, CCS, Clin Neurol, Belgrade, Serbia
[12] Nieuw Unicum, Zandvoort, Netherlands
[13] Med Univ Sofia, Sofia, Bulgaria
[14] Barzilai Govt Hosp, Dept Neurol, Ashqelon, Israel
[15] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel
[16] Univ Belgrade, Fac Med, Belgrade, Serbia
[17] Israel Multiple Sclerosis Soc, Tel Aviv, Israel
[18] Kings Coll Hosp NHS Fdn Trust, Dept Neurol, London, England
[19] FARO Charitable Fdn, Turin, Italy
[20] Univ Hosp Policlin Vittorio Emanuele, Multiple Sclerosis Ctr, Neurol Clin, Catania, Italy
[21] Univ Cologne, Fac Med, Dept Palliat Med, Cologne, Germany
[22] Univ Cologne, Univ Hosp, Cologne, Germany
[23] Univ Cologne, Fac Med, Ctr Hlth Serv Res ZVFK, Cologne, Germany
[24] Univ Kent, Tizard Ctr, Canterbury, Kent, England
关键词:
clinical practice guideline;
GRADE assessment;
multiple sclerosis;
palliative care;
EUROPEAN ASSOCIATION;
EMERGING SUBSPECIALTIES;
PARKINSONS-DISEASE;
WHITE PAPER;
DEATH;
NEUROLOGY;
RECOMMENDATIONS;
CAREGIVERS;
MANAGEMENT;
SURVIVAL;
D O I:
10.1111/ene.14248
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Background and purpose Patients with severe, progressive multiple sclerosis (MS) have complex physical and psychosocial needs, typically over several years. Few treatment options are available to prevent or delay further clinical worsening in this population. The objective was to develop an evidence-based clinical practice guideline for the palliative care of patients with severe, progressive MS. Methods This guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation methodology. Formulation of the clinical questions was performed in the Patients-Intervention-Comparator-Outcome format, involving patients, carers and healthcare professionals (HPs). No uniform definition of severe MS exists: in this guideline, constant bilateral support required to walk 20 m without resting (Expanded Disability Status Scale score > 6.0) or higher disability is referred to. When evidence was lacking for this population, recommendations were formulated using indirect evidence or good practice statements were devised. Results Ten clinical questions were formulated. They encompassed general and specialist palliative care, advance care planning, discussing with HPs the patient's wish to hasten death, symptom management, multidisciplinary rehabilitation, interventions for caregivers and interventions for HPs. A total of 34 recommendations (33 weak, 1 strong) and seven good practice statements were devised. Conclusions The provision of home-based palliative care (either general or specialist) is recommended with weak strength for patients with severe, progressive MS. Further research on the integration of palliative care and MS care is needed. Areas that currently lack evidence of efficacy in this population include advance care planning, the management of symptoms such as fatigue and mood problems, and interventions for caregivers and HPs.
引用
收藏
页码:1510 / 1529
页数:20
相关论文